This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hansen, J. E. Articles by Reeves, M. E. Search for Related Content PubMed PubMed Citation Articles by Hansen, J. E. Articles by Reeves, M. E.

Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis In vivo

¹ Veterans Affairs Greater Los Angeles Healthcare System, Sepulveda, California; ² Loma Linda Veterans Affairs Medical Center; ³ Loma Linda University, Loma Linda, California; ⁴ Olive View-University of California at Los Angeles Medical Center, Sylmar, California; and ⁵ University of California at Los Angeles David Geffen School of Medicine, Los Angeles, California

Requests for reprints: Richard H. Weisbart, Veterans Affairs Medical Center (111S), 16111 Plummer Street, Sepulveda, CA 91343. Phone: 818-895-9384; Fax: 818-895-9423; E-mail: rweisbar{at}ucla.edu.

To evaluate the clinical efficacy of monoclonal antibody (mAb) 3E10 Fv antibody-mediated p53 protein therapy, an Fv-p53 fusion protein produced in Pichia pastoris was tested on CT26.CL25 colon cancer cells in vitro and in vivo in a mouse model of colon cancer metastasis to the liver. In vitro experiments showed killing of CT26.CL25 cells by Fv-p53 but not Fv or p53 alone, and immunohistochemical staining confirmed that Fv was required for transport of p53 into cells. Prevention of liver metastasis in vivo was tested by splenic injection of 100 nmol/L Fv-p53 10 min and 1 week after injection of CT26.CL25 cancer cells into the portal vein of BALB/c mice. Mice were sacrificed 1 week after the second injection of Fv-p53 and assigned a quantitative metastasis score. Control mice had an average metastasis score of 3.3 ± 1.3, whereas mice treated with Fv-p53 had an average metastasis score of 0.8 ± 0.4 (P = 0.004). These results indicate that Fv-p53 treatment had a profound effect on liver metastasis and represent the first demonstration of effective full-length p53 protein therapy in vivo. mAb 3E10 Fv has significant clinical potential as a mediator of intracellular and intranuclear delivery of p53 for prevention and treatment of cancer metastasis. [Cancer Res 2007;67(4):1769–74]

This article has been cited by other articles:

				J. E. Hansen, C.-M. Tse, G. Chan, E. R. Heinze, R. N. Nishimura, and R. H. Weisbart, Intranuclear Protein Transduction through a Nucleoside Salvage Pathway J. Biol. Chem., July 20, 2007; 282(29): 20790 - 20793. [Abstract] [Full Text] [PDF]